conclusions pending confirmation in other studies, LV mass and LV diastolic function seem to be related to genetic variation in the steroid biosynthesis.
Endogenous ouabain (EO) is a digitalis-like steroid, which is mainly synthesized and released from the adrenal glands. 1 Aldosterone is a steroid hormone produced by adrenal gland, and is the primary regulator of sodium reabsorption in the distal tubule and collecting duct of kidney. Both steroids might play a role in the pathogenesis of left ventricular (LV) hypertrophy and cardiac remodeling. 2, 3 In previously reported population studies, we noticed that LV wall thickness increased with plasma EO, 4 whereas LV mass and LV end-diastolic diameter increased with 24-h urinary aldosterone over and beyond blood pressure and other covariables. 5 A number of enzymes are essential in the biosynthesis of steroid hormones. Cholesterol side-chain cleavage enzyme (CYP11A1) catalyzes the first and rate-limiting step in the synthesis of the steroid hormones, by converting cholesterol to pregnenolone. 3β-hydroxysteroid dehydrogenase (HSD3B1), which catalyzes the transformation of pregnenolone to progesterone, also plays a crucial role in the biosynthesis of all classes of steroid hormones. Several studies 6, 7 reported that the circulating levels of EO and aldosterone are associated with genetic variants in CYP11A1 and HSD3B1. Therefore, in the present study, we investigated whether LV structure and function might be related to tag single nucletide polymorphisms (SNPs) in CYP11A1 (rs2279357, rs11638442, and rs2073475), and HSD3B1 (rs2236780, rs3765945, and rs6203) in a European population.
Methods
Study population. Recruitment for the Flemish Study on Environment, Genes and Health Outcomes (FLEMENGHO) started in 1985. As described in detail in previous publications, 8 from August 1985 until December 2005, we recruited a random sample of families from a geographically defined area in northern Belgium. From May 2005 until June 2008, we re-invited Background both endogenous ouabain (eO) and aldosterone are steroid hormones which might play a role in the pathogenesis of left ventricular (LV) hypertrophy and cardiac remodeling. Cholesterol side-chain cleavage enzyme (CYp11A1) and 3β-hydroxysteroid dehydrogenase (HsD3b1) are two key enzymes in the pathway of steroid biosynthesis.
We investigated in 532 individuals (mean age, 50.3 years; 51.5% women) randomly recruited from a white european population whether LV structure and function were related to genetic variations in CYp11A1 and HsD3b1. We measured LV structure by conventional echocardiography and LV diastolic function by Doppler imaging of the transmitral blood flow and the mitral annular movement. We genotyped tag single nucleotide polymorphisms (sNps) rs2279357, rs11638442 and rs2073475 in CYP11A1, and rs2236780, rs3765945, and rs6203 in HSD3B1.
results
While adjusting for covariables and accounting for family clusters, LV mass index decreased (P ≤ 0.049) across the CYp11A1 genotypes in rs2279357 (CC vs. Ct vs. tt), rs11638442 (GG vs. GC vs. CC), and rs2073475 (GG vs. GA+AA). Carriers of the CYP11A1 tCG haplotype had lower (P ≤ 0.017) LV mass and LV mass index than noncarriers. Carriers of HSD3B1 GCC haplotype had lower peak early (ea; P = 0.004) and higher peak late (Aa; P = 0.066) diastolic mitral annular velocities and therefore a lower ea/Aa ratio (P = 0.041) as compared with noncarriers. Neither plasma endogenous ouabain nor 24-h urinary aldosterone were related to any of the sNps or haplotypes (P ≥ 0.07).
845 former participants for a follow-up examination including echocardiography; 667 of those renewed their consent in writing and took part (78.9%). The Ethics Committee of the University of Leuven approved the study.
For these analyses, we excluded subjects on the basis of the following criteria: (i) clinically significant heart diseases, such as myocardial infarction or coronary revascularization (n = 16), valvular heart disease (n = 27), cardiac arrhythmias or pacemaker implantation (n = 8), cardiomyopathy (n = 1), or congenital heart disease (n = 1); (ii) an echocardiogram of insufficient quality to obtain all of the structural and functional measurements (n = 26), and (iii) missing biochemical measurements (n = 8) or missing genotyping information (n = 48). Therefore, the total number of statistically analyzed participants were 532.
Echocardiography. The participants refrained from smoking, heavy exercise, or drinking alcohol for at least 3 h before echocardiography. One experienced observer (T.K.) performed all echocardiograms 4 according to the recommendations of the American Society of Echocardiography, 9 using a Vivid 7 Pro (GE Vingmed, Horten, Norway) interfaced with a 2.5-3.5 MHz phased-array probe. All recordings were digitally stored for off-line analyses by the EchoPac software package, version 4.0.4 (GE Vingmed).
We measured LV end-diastolic diameter (LVID), interventricular septum (IVS) and posterior wall thickness (PWT) on the two-dimensional guided M-mode imaging recorded from the parasternal long axis view. In case optimal orientation of the M-mode beam could not be obtained, we performed linear measurements on correctly oriented two-dimensional images. All measurements were made by the leading-edge method 10 and averaged over three cardiac cycles. Mean wall thickness was (IVS + PWT)/2, and relative wall thickness was (IVS + PWT)/LVID. We computed LV mass in grams from a validated formula 11 as 0.8 × (1.04[(LVID + IVS + PWT) 3 -LVID 3 ]) + 0.6. LV mass was indexed to body height 2.7 and body surface area (BSA), respectively. BSA was calculated as body weight 0.425 (in kg) × body height 0.725 (in cm) × 0.007184. The intra-observer intra-session variability of LV mass was 4.3%. 4 From the apical window, the sonographer placed the Doppler sample volume between the tips of the mitral valve to obtain pulsed-wave Doppler images of mitral blood flow. From the transmitral flow signal, the observer measured peak early (E) and peak late (A) diastolic velocity and calculated the E/A ratio. Tissue Doppler Imaging (TDI) is an ultrasound technique that records the velocity of myocardium instead of blood flow. The TDI-derived velocities provide information on LV diastolic function over and beyond the conventional Doppler indexes of transmitral blood flow. The observer acquired TDI of the mitral annulus by recording the low-velocity, high-frequency myocardial signals at a frame rate of at least 190 per second, while adjusting the imaging angle to ensure parallel alignment of the beam. From these TDI recordings, we determined peak early (Ea) and peak late (Aa) diastolic velocities of mitral annulus, and calculated the Ea/Aa ratio. For analysis, we averaged Ea and Aa measured from septal, lateral, posterior, and inferior annular sites. 12 Other measurements. Body mass index was weight in kilograms divided by the square of height in meters. After the subjects had rested for 5 min in the sitting position, the nurses obtained five consecutive blood pressure readings (phase V diastolic pressure) to the nearest 2 mm Hg, using a standard mercury sphygmomanometer. For analysis, the five blood pressure readings were averaged. Hypertension was a blood pressure of at least 140 mm Hg systolic or 90 mm Hg diastolic, or using of antihypertensive medicines. Trained nurses administered a standardized questionnaire to collect information on the participants' medical history, smoking and drinking habits, and intake of medications. From the type and quantity of the alcoholic beverages used, we computed alcohol consumption in grams per day. We defined regular drinking as an alcohol consumption of at least 5 g per day.
On the day of the echocardiographic examination, after the individuals had rested in the supine position for at least 45 min, venous blood samples were collected into ethylenediaminetetraacetic acid tubes. After centrifuging, the plasma was separated, divided, and stored at -80 °C. EO was extracted from plasma and measured using a specific radioimmunoassay. 13 The participants also collected a 24-h urine sample in a wide-neck plastic container. Sodium and potassium were determined by flame photometry, creatinine by an automated enzymatic method, and aldosterone concentration by radioimmunoassay.
Genotyping method. We extracted DNA from white blood cells. Table 1 lists the gene map location, function and the allele frequencies of selected tag SNPs of CYP11A1 (rs2279357, rs11638442, and rs2073475) and HSD3B1 (rs2236780, rs3765945, and rs6203). For genotyping, we used a 5′ nuclease detection assay implemented on an ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA). Primers, probes, and polymerase chain reaction conditions for genotyping have been described in detail elsewhere. 7 Statistical methods. For database management and statistical analyses, we used SAS software (SAS Institute, Cary, NC), version 9.1.3. Continuous data are presented as mean ± standard deviation and categorical data as percentages. We normalized the distributions of plasma EO and aldosterone by a logarithmic transformation. We compared means and proportions, using ANOVA and the the χ 2 statistic, respectively. We tested the Hardy-Weinberg equilibrium and reconstructed haplotypes, using the PROC ALLELE and PROC HAPLOTYPE procedure implemented in the genetics module of the SAS software. We used a codominant model except if the prevalence of the least frequent genotype or haplotype was less than 5%, in which case we applied the dominant model by combining it with the heterzygotes. We applied a generalization of the standard linear model, as implemented in the PROC MIXED procedure of the SAS package, to investigate the associations of the echocardiographic measurements with genetic variants, while accounting for relatedness and adjusting for covariables. Covariates with known physiologic relevance for LV structure and function [14] [15] [16] were included as fixed effects, while family was moduled as a random effect.
results characteristics of the participants
Our study sample included 418 participants from 46 families and 114 unrelated individuals. Of the 532 participants, 274 (51.5%) were female and 210 (39.5%) had hypertension, of whom 111 (20.1% of all participants, 52.3% of hypertensive subjects) were taking antihypertensive medications. Mean age was 50.3 ± 13.7 (SD) years and ranged from 16 to 90 years. Of all participants, 64 women (23.3%) and 57 men (21.8%) were smokers; 70 women (25.5%) and 163 men (62.5%) reported an alcohol intake of at least 5 g/day. In smokers, median tobacco use was 12 cigarettes per day (interquartile range, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . In regular drinkers, the median alcohol consumption was 11 g/ day (interquartile range, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Table 2 lists the characteristics of the participants by sex. As compared with women, men were younger and had higher blood pressure. Men reported more frequent alcohol intake than women (62.5% vs. 25.5%, P < 0.001) and had higher 24-h urinary sodium excretion (197.1 vs. 145.7 mmol/day). Table 3 lists the echocardiographic variables by sex. LV mass, LV mass index, LV diameter and wall thickness were significantly higher in men than in women (P < 0.001). The mitral flow velocity E and A peaks were higher in women than in man (P < 0.001). The E/A ratio and the TDI-derived mitral annulus myocardium velocities were similar in women and men (P > 0.06).
genotypes and haplotype frequencies
The genotype frequencies of the tag SNPs in CYP11A1 and HSD3B1 are shown in Table 4 and complied with HardyWeinberg equilibrium (0.17 < P < 0.91). The r 2 reflected linkage disequilibrium between these tag SNPs ranged from 0.49 to 0.86 (Supplementary Table S1, online). We constructed haplotypes of CYP11A1 and HSD3B1 gene by using available SNPs (Supplementary Table S2 , online). Haplotype frequencies for CYP11A1 were 10% CCG, 15% TCA, 18% TCG, and 57% CGG. For HSD3B1 the haplotype frequencies were 7% GCC, 24% GTC, 34% GTT, and 35% ACC, respectively. Because of the linkage disequilibrium of these SNPs, only the haplotypes Values are mean ± SD, geometric mean (interquartile range) or number of subjects (%). P values are for the sex differences. BP, blood pressure; bpm, beat per minute; EO, endogenous ouabain.
CCG and TCG of CYP11A1, and GCC and GTC of HSD3B1 provided additional information beyond SNPs.
lV structure
We adjusted the LV structure phenotypes for sex, age, body weight (not applicable to LV mass/BSA), and body height (not applicable to LV mass/height 2.7 and LV mass/BSA), systolic blood pressure, heart rate, smoking and drinking alcohol, antihypertensive treatment, and 24-h urinary sodium excretion. Although adjusting for these covariables and accounting for family clusters (Table 4) , we noticed significant decreases (P ≤ 0.049) of LV mass and mass index across the CYP11A1 genotypes in rs2279357 (CC vs. CT vs. TT), rs11638442 (GG vs. GC vs. CC), and rs2073475 (GG vs. GA+AA). In multivariable-adjusted analyses, the variance of LV mass explained by the three CYP11A1 genotypes ranged from 1.1 to 2.4%. The genotypic differences in LV mass and LV mass index were mainly because of the differences in end-diastolic diameter.
Haplotype analysis revealed that in subjects with TCG haplotype of CYP11A1 gene, LV mass (167.5 vs. 174.6 g; P = 0.010), LV mass/ height 2.7 (39.7 vs. 42.0 g/m 2.7 ; P = 0.001) and LV mass/BSA (89.9 vs.93.4 g/m 2 ; P = 0.017) were significantly lower in carriers than in noncarriers ( Table 5) . LV phenotypes did not show any difference between carriers and noncarriers of all the other informative haplotypes of CYP11A1 and HSD3B1.
lV diastolic function
As in previous analyses, 16 we adjusted the indexes of LV diastolic function for sex, age, body mass index, diastolic blood pressure, heart rate, antihypertensive treatment and 24-h urinary sodium excretion. Although adjusting for covariables and accounting for relatedness, none of the investigated SNPs was associated with the Doppler indexes of LV diastolic function. Haplotype analysis revealed that carriers of HSD3B1 GCC haplotype had a lower Ea peak (11.2 vs.11.9 cm/s, P = 0.004), a higher Aa peak (10.6 vs. 10.3 cm/s, P = 0.066) and therefore a lower Ea/Aa ratio (1.17 vs. 1.25, P = 0.041) as compared with noncarriers ( Table 5 ). The HSD3B1 GCC haplotype explained 1.6% of the variance in the Ea peak and 0.6% of the variance in the Aa peak.
Plasma eo and 24-h urinary aldosterone
We further investigated the association of plasma EO and 24-h urinary aldosterone excretion with those tag SNPs. As previously, 7 we adjusted plasma EO for sex, age and body mass index, and 24-h urinary aldosterone for sex, age, body mass index, and the urinary sodium-to-potassium ratio. Neither plasma EO nor 24-h urinary aldosterone were related to any of the investigated SNPs or haplotypes (P ≥ 0.07).
discussion
The key findings of the present study were that in a Caucasian population, LV mass was associated with genetic variation in the CYP11A1 gene, and that TDI-derived indexes of LV diastolic function were related to the HSD3B1 GCC haplotype. We did not observe any association of the genetic variants under study with plasma EO or 24-h urinary aldosterone.
According to our knowledge, no previous study ever reported on the association of LV phenotypes with the CYP11A1 gene. The cholesterol side-chain cleavage enzyme CYP11A1 belongs to the cytochrome P450 family, which are membrane-bound proteins involved in steroid hormone biosynthesis. CYP11A1 catalyzes the conversion of cholesterol to pregnenolone, which is the first and rate-limiting step in the biosynthesis of all steroid hormones, including progesterone, estrogen, androgens, and aldosterone. This gene is located on human chromosome 15q23-q24, is approximately 30 kb long, and consists of nine exons. CYP11A1 is mainly expressed in the adrenal cortex, ovaries, placenta, and testis, and to a lesser extent in the central and peripheral nervous system 17 and in the heart. 18, 19 CYP11A1 mRNA is expressed in the normal human heart in the left and right atria, the left and right ventricles, aorta, apex, the interventricular septum, and the atrioventricular node, 18 but at levels approximately 100-1000 fold lower than those in the adrenal gland. 18 rs2279357 and rs11638442 are in the introns of CYP11A1 while rs2073475 is located less than 2 kb from upstream transcription start site. Their exact functions remain unknown and it is likely that those variants are in linkage disequilibrium with nearby functional variants. We found significant association of LV mass with genetic variants of CYP11A1 gene, but the underlying mechanisms remain unclear.
Human 3β-hydroxysteroid dehydrogenase, belongs to the short-chain alcohol dehydrogenase reductase superfamily, and is also a rate-limiting enzyme in the steroid biosynthesis. It is expressed as two-tissue specific isoforms (HSD3B1 and HSD3B2) with different substrate affinities. HSD3B1 catalyzes the conversion of pregnenolone to progesterone. The human HSD3B1 gene is located on chromosome 1p12, is approximately 8 kb long, and consists of four exons. It is expressed in placenta, skin, and breast tissue. Young et al. 19 reported the expression of HSD3B1 in the left and right atria, and in the left and right ventricles of the human heart. However, in a recent study reported by Chai et al., 20 HSD3B1 expression was negative in all 42 tissue samples from heart-beating human organ donors, patients with end-stage heart failure or hypertrophic cardiomyopathy. rs6203 is a synonymous mutation in the last exon of HSD3B1 gene. Synonymous mutations may be included in a specific short oligonucleotide sequence that affects exon splicing. 21 Therefore, rs6023 might play a role in gene regulation. Rosmond et al. 22 reported that in 284 51-yearold untreated men, HSD3B1 rs6203 CC homozygotes had significantly higher mean systolic and diastolic blood pressures as compared with T allele carriers. In contrast, Speirs et al. 23 did not find any association of hypertension with this SNP and in 168 unrelated Caucasian hypertensive patients and 312 normotensive controls. Mineralocorticoid excess might lead to cardiac remodeling. Mineralocorticoid receptor antagonists regress hypertrophy, fibrosis, and diastolic dysfunction in human and experimental hypertensive heart disease, 24, 25 whereas these phenotypes are induced by mineralocorticoid excess. 26 In previous studies, on the basis of the same population as included in the current report, we investigated the association of LV structure with plasma EO and 24-h urinary aldosterone. Kuznetsova et al. 4 showed that for 1-SD increment in plasma EO (0.21 on the base-10 logarithmic scale), systolic blood pressure, LV posterior wall, the interventricular septum, and relative wall thickness increased by 1.59 mm Hg (P = 0.009), 0.138 mm (P = 0.003), 0.152 mm (P = 0.013), and 0.71 × 10 −2 (P = 0.008), respectively. In the second study, 5 LV mass index independently increased with 24-h urinary aldosterone. This association was because of higher LV end-diastolic diameter, but not mean wall thickness. Thus it is possible that genetically induced structural changes mediated by steroid biosynthesis also contribute to the currently observed association of LV diastolic function with HSD3B1. In the current report, we observed that TDI-derived indexes of LV diastolic function were related to the HSD3B1 GCC haplotype. To the best of our knowledge, only one previous study addressed the possible association of LV phenotypes with HSD3B1. Shimodaira et al. 27 found an Wall thickness (mm) 9.78 ± 0.10 9.59 ± 0.10 9.48 ± 0.15 0.064 9.68 ± 0.10 9.70 ± 0. association of plasma aldosterone levels but not LV hypertrophy with genetic variants in the HSD3B1 gene in a case-control study including 275 untreated Japanese hypertensive patients and 286 controls. In our analysis, we did not find any association of 24-h urinary aldosterone or circulating EO with genetic variants in CYP11A1 or HSD3B1. However, the currently observed genetic variant association with LV structure and function might be mediated by alterations in the local biosynthesis in the heart rather than by systemic changes in the steroid levels. The two enzymes involved in the final pathway of corticoid synthesis 11β-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) mRNA are expressed in the rat heart. 28 Takeda et al. 29 detected cardiac aldosterone, aldosterone synthase activity, and CYP11B2 mRNA in hearts of stroke-prone spontaneously hypertensive rats after bilateral adrenalectomy, and spironolactone prevented cardiac hypertrophy in those rats. However, reports on whether CYP11B1 and CYP11B2 are expressed in the human heart are contradictory. KayesWandover and White 18 detected CYP11B2 mRNA in the aorta and fetal heart, but not in any region of the adult heart. Other investigator reported the presence of CYP11B1 and CYP11B2 mRNA in the failing heart but not in the normal human hearts. 19 Another possibility to be considered is that CYP11A1 and HSD3B1 are involved in the biosynthesis of all steroid hormones and that the currently observed genetic associations might not be mediated via changes in the synthesis of ouabain, aldosterone or mineralocorticoids.
Our study results have to be interpreted within the context of their potential limitations. First, we did not sequence the entire human CYP11A1 or HSD3B1 gene. Instead, we selected previously identified tag SNPs on the basis of the evidence from pre- 2.7 and LV mass/BSA), systolic blood pressure, heart rate, smoking and drinking alcohol, antihypertensive treatment and 24-h urinary sodium excretion for left ventricular structure, and sex, age, body mass index, diastolic blood pressure, heart rate, antihypertensive treatment (0, 1) and 24-h urinary sodium excretion for LV diastolic function. P values are for the difference between genotypes with adjustments applied. BSA, body surface area; LV, left ventricular.
vious experimental and human studies. Although there is no direct evidence supporting the functionality of these SNPs, previous research does indicate that these tagged loci are associated with steroid hormone levels, such as EO. 7 Second, we did not measure steroid hormones other than EO and aldosterone or evaluate key regulatory enzymes in the biosynthesis of steroids. However, such comprehensive measurements would require standardized laboratory conditions and highly motivated volunteers. These conditions of measurements are not achievable in the epidemiological setting. Third, the mixed model considers family members as clusters and assumes the same degree of dependency among all the family members, therefore our analyses did not account for the position of each member within the pedigree. This might have introduced attenuation bias. Fourth, our sample size was relatively small and we tested only six tag SNPs from two genes. Assuming a minor allele frequency of 35%, our study had 20% power to detect a 10% difference of plasma EO or 24-h aldosterone excretion between different genotypes with a 2-side P value of 0.05. Our power increased to 60% for a 20% difference of plasma EO or 24-h aldosterone excretion between different genotypes. Fifth, adjustment for multiple comparisons is usually recommended to avoid rejecting the null hypotheses too readily. However, because our tag SNPs were in linkage disequilibrium, each test does not provide a completely independent opportunity for a type I error. Sixth, LV phenotypes are quantitative traits prone to measurement errors. Cardiac magnetic resonance imaging provides a more precise estimate of LV mass. However, magnetic resonance imaging is expensive and time consuming, and therefore cannot be easily applied in population studies. Moreover, echocardiography remains the most practical method to estimate LV diastolic function because of its superior temporal resolution.
In conclusion, pending confirmation in other studies, LV mass and LV diastolic function seem to be related to genetic variation in the steroid biosynthesis. Whether or not these findings can be explained by systemic effects of steroids as reflected by plasma EO or urinary aldosterone or by the modulation of the local production of steroids in the heart remains to be elucidated.
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